ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Results 1 - 20 of 40 : 1 2 Next »

Recs

0
Member Avatar craze191st (70.85) Submitted: 10/17/2014 2:35:21 PM : Outperform Start Price: $25.83 ACAD Score: -1.40

Primavanserin is sure to be a hit.

Recs

0
Member Avatar sam5454 (< 20) Submitted: 6/26/2014 7:25:26 PM : Outperform Start Price: $22.65 ACAD Score: +16.51

FDA approval is almost certain. A buyer will appear.

Recs

0
Member Avatar molmaemo (< 20) Submitted: 4/22/2014 11:23:26 AM : Outperform Start Price: $21.01 ACAD Score: +21.91

Every neighborhood block has a home for Alzheimer's patients. WE NEED TO MAKE THIS WORK. These diseases are overwhelming health care!

Recs

0
Member Avatar 2win (< 20) Submitted: 1/11/2014 12:36:28 PM : Outperform Start Price: $23.94 ACAD Score: +4.11

rebuying lower

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:54:50 AM : Underperform Start Price: $22.34 ACAD Score: -10.49

Catalysts too far out. Stock overbought.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/9/2013 6:11:31 PM : Underperform Start Price: $21.78 ACAD Score: -11.09

top hs pattern

Recs

0
Member Avatar NuclearSteve (68.91) Submitted: 10/9/2013 12:22:29 PM : Outperform Start Price: $20.81 ACAD Score: +8.71

Huge drop with no basis. To toot my own horn, I timed this *PERFECTLY* :) Now is the time to get back in. Still believe pimavanserin makes this a $60 stock in 2 years.

Recs

0
Member Avatar stardog900 (< 20) Submitted: 7/27/2013 2:08:23 PM : Outperform Start Price: $18.51 ACAD Score: +26.97

If trials are successful, as is anticipated, this stock should outperform the S&P 500 greatly over the next year or two. Potential for large increase in value long term.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:14:01 AM : Outperform Start Price: $19.57 ACAD Score: +15.45

Multiple new compounds fill an open void. Little price competition will protect profit margins.

Recs

0
Member Avatar 78taxs (< 20) Submitted: 6/10/2013 10:11:54 PM : Outperform Start Price: $18.85 ACAD Score: +20.33

Its the best drug on the way.

Recs

0
Member Avatar TMFBiologyFool (96.75) Submitted: 11/27/2012 4:18:10 PM : Underperform Start Price: $4.92 ACAD Score: -396.44

No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 11/24/2012 5:00:23 PM : Outperform Start Price: $2.23 ACAD Score: +1,043.61

Good Phase 3 coming

Recs

4
Member Avatar zzlangerhans (99.81) Submitted: 11/23/2012 8:23:49 PM : Underperform Start Price: $2.17 ACAD Score: -1,077.25

I was going to sit this one out, but then I remembered how much I regretted my decision not to red thumb Zalicus ahead of SYNERGY and I decided to go for it. The initial phase III trial of pimavanserin for Parkinson's psychosis failed in 2009 and the simultaneous phase III trial was canceled. I've heard all kinds of reasons why the current phase III trial will be successful (tweaking of clinical sites, entry criteria, study endpoints) but the fact is that most phase III redos fail. Pimavanserin wasn't even Acadia's first major failure - that came in 2008 with the termination of ACP-104 development for schizophrenia.

Even if I'm wrong and the phase III trial is a success, I could still escape this pick with a positive score as the market digests the reality that Acadia will have to run another phase III trial before approval, cash is low, the likelihood of heavy dilution is certain, and pimavanserin will still eventually have to compete with inexpensive generic antipsychotics. Regardless, I have only meaningless CAPS points to lose and all kinds of schadenfreude to gain.

Recs

0
Member Avatar mekadik (< 20) Submitted: 7/22/2012 3:08:08 PM : Outperform Start Price: $1.50 ACAD Score: +1,593.05

very good chance for approval

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 7:42:42 PM : Outperform Start Price: $1.87 ACAD Score: +1,251.74

New study results to be released soon.

Recs

0
Member Avatar jwpao (54.07) Submitted: 6/24/2012 8:16:49 AM : Outperform Start Price: $1.49 ACAD Score: +1,601.52

no debt

Recs

0
Member Avatar SIDRWC (67.61) Submitted: 3/30/2012 1:16:24 PM : Outperform Start Price: $2.13 ACAD Score: +1,082.73

Financial backers are extremely strong and are driving this company.

Recs

0
Member Avatar RBuskey106 (37.74) Submitted: 3/28/2012 9:22:51 PM : Outperform Start Price: $2.15 ACAD Score: +1,072.98

Chart play. Bottoming here.

Recs

0
Member Avatar tcoss (30.17) Submitted: 4/28/2011 10:26:03 PM : Outperform Start Price: $2.98 ACAD Score: +731.68

I do have my worries about this pick. They do have plenty of cash and a phase III trials in the works. Really this is a bet on the phase III trials.

Recs

0
Member Avatar drmanand (66.77) Submitted: 6/17/2010 8:25:07 PM : Outperform Start Price: $1.11 ACAD Score: +2,170.76

Has very important nitch new medications.
a strong buy.

Results 1 - 20 of 40 : 1 2 Next »

Featured Broker Partners


Advertisement